Solara Active Pharma Sciences Limited

BSE:541540 Stock Report

Market Cap: ₹31.7b

Solara Active Pharma Sciences Past Earnings Performance

Past criteria checks 0/6

Solara Active Pharma Sciences's earnings have been declining at an average annual rate of -72.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been declining at an average rate of 1.7% per year.

Key information

-72.5%

Earnings growth rate

-71.9%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate-1.7%
Return on equity-49.3%
Net Margin-43.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Solara Active Pharma Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:541540 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2412,218-5,3612,3240
30 Jun 2413,001-5,6132,3780
31 Mar 2412,889-5,6742,5000
31 Dec 2314,069-3,0772,5030
30 Sep 2315,529-3252,4610
30 Jun 2314,661-2532,3590
31 Mar 2314,438-2222,3080
31 Dec 2214,240-2412,1500
30 Sep 2211,296-1,6442,2210
30 Jun 2211,928-1,2472,3190
31 Mar 2212,683-5812,3920
31 Dec 2113,517-342,5290
30 Sep 2116,7812,0232,4720
30 Jun 2116,7402,2932,3930
31 Mar 2116,1692,2142,3270
31 Dec 2014,6941,8262,2970
30 Sep 2013,8641,5812,2120
30 Jun 2013,4001,3042,1390
31 Mar 2013,2181,1462,0800
31 Dec 1914,1031,2312,0590
30 Sep 1914,2281,0392,0320
30 Jun 1914,1408451,9860
31 Mar 1913,8676141,9270
31 Mar 185,210607100

Quality Earnings: 541540 is currently unprofitable.

Growing Profit Margin: 541540 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 541540 is unprofitable, and losses have increased over the past 5 years at a rate of 72.5% per year.

Accelerating Growth: Unable to compare 541540's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 541540 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (20.4%).

Return on Equity

High ROE: 541540 has a negative Return on Equity (-49.26%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:03
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Solara Active Pharma Sciences Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullAntique Stockbroking Ltd.
Kameswari V. S. ChavaliFirstCall Research
Rishabh KaleIndsec Securities & Finance Ltd.